• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/12/21 9:55:28 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLSD alert in real time by email
    SC 13G/A 1 form-sc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No. 2)*

     

    Clearside Biomedical, Inc.

     

    (Name of Issuer)

     

    Common Stock

     

    (Title of Class of Securities)

     

    185063104

     

    (CUSIP Number)

     

    December 31, 2020

     

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    [  ] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [  ] Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      RTW Investments, LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
       
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0 
       
    6. SHARED VOTING POWER
       
     

    3,958,130*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    3,958,130*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    3,958,130*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    8.19%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      PN, OO, IA

     

     
     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      RTW Master Fund, Ltd.
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
           
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
     

    2,766,023*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    2,766,023*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    2,766,023*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    5.72%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      CO

     

     
     

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Roderick Wong
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
          (a) [  ]
          (b) [X]
           
    3. SEC USE ONLY
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States of America
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
     

    3,958,130*

       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
     

    3,958,130*

       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
     

    3,958,130*

       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
          [  ]
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
     

    8.19%*

       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IN, HC

     

     
     

     

    Item 1. (a).

    Name of Issuer:

     

    Clearside Biomedical, Inc.

         
         
      (b). Address of issuer’s principal executive offices:
         
       

    900 North Point Parkway, Suite 200

        Alpharetta, GA 30005
         
         
    Item 2. (a). Name of person filing:
         
        RTW Investments, LP
        RTW Master Fund, Ltd.
        Roderick Wong
         
         
      (b). Address or principal business office or, if none, residence:
         
        RTW Investments, LP
        40 10th Avenue
        Floor 7
        New York, New York 10014
         
        RTW Master Fund, Ltd.
        c/o Intertrust Corporate Services (Cayman) Limited
        190 Elgin Avenue, George Town
        Grand Cayman KY1-9001, Cayman Islands
         
        Roderick Wong
        c/o RTW Investments, LP
       

    40 10th Avenue

        Floor 7
        New York, New York 10014
         
         
      (c). Citizenship:
         
        RTW Investments, LP – Delaware
        RTW Master Fund, Ltd. – Cayman Islands
        Roderick Wong – United States of America
         
         
      (d). Title of class of securities:
         
        Common Stock
         
         
      (e). CUSIP No.:
         
        185063104
         

     

     
     

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
       
      N/A
       
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
           
      (a) Amount beneficially owned:
           
          RTW Investments, LP – 3,958,130*
          RTW Master Fund, Ltd. – 2,766,023*
          Roderick Wong – 3,958,130*
           
             
      (b) Percent of class:
           
          RTW Investments, LP – 8.19%*
          RTW Master Fund, Ltd. – 5.72%*
          Roderick Wong – 8.19%*
           
           
      (c) Number of shares as to which the person has:
           
          (i) Sole power to vote or to direct the vote
             
            RTW Investments, LP – 0
            RTW Master Fund, Ltd. – 0
            Roderick Wong – 0
             
          (ii) Shared power to vote or to direct the vote
             
            RTW Investments, LP – 3,958,130*
            RTW Master Fund, Ltd. – 2,766,023*
            Roderick Wong – 3,958,130*
             
          (iii) Sole power to dispose or to direct the disposition of
             
            RTW Investments, LP – 0
            RTW Master Fund, Ltd. – 0
            Roderick Wong – 0
             
          (iv) Shared power to dispose or to direct the disposition of
             
            RTW Investments, LP – 3,958,130*
            RTW Master Fund, Ltd. – 2,766,023*
            Roderick Wong – 3,958,130*

     

     

     

    * The Common Stock (the “Shares”), of Clearside Biomedical, Inc. (the “Company”) reported herein are held by RTW Master Fund, Ltd. and one or more private funds (together the “Funds”) managed by RTW Investments, LP (the “Adviser”). The Adviser, in its capacity as the investment manager of the Funds, has the power to vote and the power to direct the disposition of all Shares held by the Funds. Accordingly, for the purposes of Reg. Section 240.13d-3, the Adviser may be deemed to beneficially own an aggregate of 3,958,130 Shares, or 8.19% of the Company’s 48,353,952 Shares deemed issued and outstanding as of November 6, 2020, as disclosed in the Company’s 10-Q Quarterly Report, as filed with the Securities and Exchange Commission on November 10, 2020. Roderick Wong is the Managing Partner of the Adviser. This report shall not be deemed an admission that the Adviser, the Funds or any other person is the beneficial owner of the securities reported herein for purposes of Section 13 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Each of the reporting persons herein disclaims beneficial ownership of the Shares reported herein except to the extent of the reporting person’s pecuniary interest therein.

     

     

     
     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].

       
      N/A
       
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
     

    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

       
      N/A
       
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
     

    If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

       
      N/A
       
       
    Item 8. Identification and Classification of Members of the Group.
       
     

    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.

       
      N/A
       
       
    Item 9. Notice of Dissolution of Group.
       
     

    Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

       
      N/A
       
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 12, 2021    
         
      RTW Investments, LP
         
      By: /s/ Roderick Wong
        Roderick Wong, Managing Partner
         
      RTW Master Fund, Ltd.
         
      By: /s/ Roderick Wong
        Roderick Wong, Director
         
      Roderick Wong
         
      By: /s/ Roderick Wong
        Roderick Wong, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Get the next $CLSD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CLSD

    DatePrice TargetRatingAnalyst
    7/18/2025$2.00Buy → Hold
    Stifel
    7/18/2025Buy → Neutral
    Chardan Capital Markets
    7/18/2025Buy → Neutral
    H.C. Wainwright
    8/21/2024$6.00Buy
    Chardan Capital Markets
    6/25/2024$5.00Outperform
    Oppenheimer
    3/11/2022$11.00 → $10.00Market Outperform
    JMP Securities
    12/15/2021$19.00 → $9.00Outperform
    Wedbush
    7/29/2021$10.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CLSD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Clearside Biomedical downgraded by Stifel with a new price target

    Stifel downgraded Clearside Biomedical from Buy to Hold and set a new price target of $2.00

    7/18/25 8:10:27 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical downgraded by Chardan Capital Markets

    Chardan Capital Markets downgraded Clearside Biomedical from Buy to Neutral

    7/18/25 8:08:24 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Clearside Biomedical from Buy to Neutral

    7/18/25 8:08:24 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    SEC Filings

    View All

    Clearside Biomedical Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Leadership Update

    8-K - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/14/25 4:05:30 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by Clearside Biomedical Inc.

    10-Q - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/8/25 4:05:49 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Clearside Biomedical Inc.

    DEF 14A - Clearside Biomedical, Inc. (0001539029) (Filer)

    8/4/25 8:00:10 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    2/24/25 5:52:59 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chong Ngai Hang Victor bought $36,500 worth of shares (36,500 units at $1.00), increasing direct ownership by 57% to 100,000 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    11/4/24 4:15:04 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Medical Officer Chong Ngai Hang Victor bought $24,910 worth of shares (23,500 units at $1.06), increasing direct ownership by 59% to 63,500 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    6/24/24 4:38:02 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Clearside Biomedical Announces Approval of XIPERE® Suprachoroidal Treatment for Uveitic Macular Edema in Canada

    - XIPERE Now Approved for Use in Multiple Global Markets - - Continued Global Expansion and Validation of Clearside's Suprachoroidal Space Injection Platform Featuring its Commercially Proven SCS Microinjector® - ALPHARETTA, Ga., July 23, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Health Canada has granted approval for XIPERE® (triamcinolone acetonide injectable suspension) for suprachoroidal use in the treatment of uveitic macular edema (UME). XIPERE is approved for use in the United States, Canada, Australia

    7/23/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Announces Plan to Explore Strategic Alternatives to Advance its Proprietary Suprachoroidal Space (SCS®) Delivery Platform and Promising Ophthalmology Pipeline

    - Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery Platform with Five Commercial and Late-Stage Development Suprachoroidal Licensing Collaborations - ALPHARETTA, Ga., July 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), today announced plans to explore a full range of strategic alternat

    7/17/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical to Participate in a Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum

    ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that management will participate in a fireside chat at the Stifel 2025 Virtual Ophthalmology Forum on Tuesday, May 27, 2025, at 9:00 a.m. ET. A link to the live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. An archive of the webcast will be available for three months. About Clearside Biomedical, Inc. Clearside Biomedical, Inc. is a biopharmaceutical company revolutionizing the de

    5/21/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for XIPERE issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug XIPERE (ORIG-1) with active ingredient TRIAMCINOLONE ACETONIDE has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:22:37 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for SUSVIMO issued to CLEARSIDE BIOMEDICAL, INC

    Submission status for CLEARSIDE BIOMEDICAL, INC's drug SUSVIMO (ORIG-1) with active ingredient RANIBIZUMAB has changed to 'Approval' on 10/22/2021. Application Category: NDA, Application Number: 211950, Application Classification: Type 3 - New Dosage Form

    10/25/21 2:07:19 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Thorp Clay bought $13,800 worth of shares (15,000 units at $0.92), increasing direct ownership by 9% to 176,141 units (SEC Form 4)

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    2/24/25 5:52:59 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Financial Officer Deignan Charles A.

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    1/10/25 4:30:10 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Medical Officer Chong Ngai Hang Victor

    4 - Clearside Biomedical, Inc. (0001539029) (Issuer)

    1/10/25 4:30:07 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Leadership Updates

    Live Leadership Updates

    View All

    Clearside Biomedical Appoints Tony Gibney as New Chair of the Board of Directors

    ALPHARETTA, Ga., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Tony Gibney as Chair of its Board of Directors, effective November 1, 2024. Mr. Gibney, who joined Clearside's Board as an independent director in April 2024, succeeds Clay Thorp, who will continue serving as a member of the Board. George Lasezkay, PharmD, JD, President and Chief Executive Officer, Clearside Biomedical, commented, "Tony is a highly respected member of our Board, bringing a wealth of strategic leadership experie

    11/4/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Appoints Dr. Glenn Yiu to its Scientific Advisory Board

    ALPHARETTA, Ga., July 11, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today the appointment of Glenn C. Yiu, M.D., Ph.D., Professor of Ophthalmology at the University of California, Davis, to its Scientific Advisory Board (SAB), which is comprised of industry-leading retinal physicians who provide medical and scientific expertise and input on the Company's research and development programs. "We are privileged to welcome Dr. Yiu to our SAB, given his leadership in the research and adoption of new delivery approaches for t

    7/11/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors

    ALPHARETTA, Ga., April 16, 2024 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that Anthony S. Gibney has been appointed to the Company's Board of Directors, effective April 15, 2024. "We are delighted to welcome Tony to our Board of Directors as we build on our leadership in delivering therapeutics to the suprachoroidal space," said Clay Thorp, Chair of the Clearside Board of Directors. "We believe Tony's significant experience driving value for biotech companies through successful pipeline development, financing, partnerin

    4/16/24 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Financials

    Live finance-specific insights

    View All

    Clearside Biomedical to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025

    ALPHARETTA, Ga., May 08, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its first quarter 2025 financial results will be reported on Wednesday, May 14, 2025 after the close of the financial markets. The Company will not be hosting a conference call this quarter. Information about the Company's quarterly results, conference calls, webcasts and other investor information is available in the Investors section of the Company's website. About Clearside Biomedical, Inc. Clearsid

    5/8/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

    - Successful End-of-Phase 2 Meeting with FDA Results in Alignment on Phase 3 Plans for CLS-AX in Wet AMD - - Asia-Pacific Partner's New Drug Application for ARCATUS® (XIPERE®) for Uveitic Macular Edema Accepted for Regulatory Review in China - - Multiple Medical Meeting Presentations Highlight Potential Advantages and Key Differentiators of Suprachoroidal Drug Delivery Utilizing Clearside's SCS Microinjector® - - Management to Host Webcast and Conference Call Today at 4:30 P.M. ET - ALPHARETTA, Ga., March 27, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the

    3/27/25 4:05:00 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

    ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD) ("Clearside" or the "Company"), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2024 financial results will be reported on Thursday, March 27, 2025 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update. The live and archived webcast may be accessed on the Clearside website under the Investors section: Events and Presentations. The live call ca

    3/12/25 7:05:00 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CLSD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    11/1/23 4:04:12 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    2/14/23 10:29:32 AM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Clearside Biomedical Inc. (Amendment)

    SC 13G/A - Clearside Biomedical, Inc. (0001539029) (Subject)

    2/13/23 12:19:46 PM ET
    $CLSD
    Biotechnology: Pharmaceutical Preparations
    Health Care